About Hemosonics
Hemosonics is a Healthcare company based in Charlottesville (United States) founded in 2004, and was acquired by Diagnostica Stago in May 2017. IVD for hemostasis characterization. Hemosonics has raised $24.92 million across 9 funding rounds from investors including HHS, Diagnostica Stago and U.S. Air Force. Hemosonics has completed 1 acquisition, including Diagnostica Stago. Hemosonics offers products and services including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Coagulopathies. Its legal entity is HemoSonics, LLC. Its competitors include Perosphere Technologies, Atantares and Stasys; 2 of its 3 listed competitors have raised funding.
Company details
HemoSonics is a privately held medical device company founded to develop and bring to market innovative in vitro diagnostics to characterize hemostasis in a variety of clinical settings. These systems employ a patented approach named sonorheometry (SR). The products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. The company claims that this approach makes their system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. This technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors. Sonorheometry has been demonstrated in a series of peer-reviewed scientific publications and has undergone both laboratory and clinical evaluation. Standalone prototypes are undergoing further clinical and laboratory evaluation. HemoSonics LLC is developing a POC instrument, the Global Hemostasis Analyzer (GHA) that can quantify the function of the four hemostatic components, enabling correct selection of treatment. The Quantra is based on sonorheometry (SR), a novel technology able to assess not only time to clot (dependent upon the plasma coagulation factors) but also clot formation rate (dependent upon fibrinogen), clot stiffness (dependent upon fibrinogen and platelets), and time to lysis (dependent upon clot-dissolving proteins)
- Headquarters Charlottesville, United States
- Stage Acquired
- SectorsHealthcare
- Website hemosonics.com
- Social LinkedIn X YouTube
- Acquired by Diagnostica Stago (May 2017)
- Legal Name Hemosonics, Llc
- Total Equity Funding$24.92M (USD)
in 9 rounds
- Latest Funding Round$15M (USD), Series B
Feb 2017
- InvestorsHHS
& 3 more
- Investments & Acquisitions
- Acquired byDiagnostica Stago
(May 2017)
Products & Services of Hemosonics
Hemosonics offers a comprehensive portfolio of products and services, including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program.
Device for viscoelastic testing of blood coagulation in surgical settings.
Cartridge for coagulation evaluations in point-of-care applications.
Cartridge to assess hypocoagulable and hypercoagulable conditions in trauma.
Kits for ensuring accuracy in hemostasis testing procedures.
Program for external quality assessment of hemostasis testing.
Apps and channels of Hemosonics
its YouTube channel HemoSonics has 398 subscribers and 23 videos.
Videos from Hemosonics
The most watched videos on Hemosonics's YouTube channel, HemoSonics (398 subscribers). Click a video to play it here.
More on HemoSonics.
Funding Insights of Hemosonics
Hemosonics has successfully raised a total of $24.92M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.92M
- Total Rounds 9
- Last Round Series B — $15M
- First Round $1M
(Jun 2010)
- Investors Count 3
All 9 funding rounds of Hemosonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $15M | Series B | – | – | – |
| Aug 2016 | $3.97M | Series A | – | – | – |
| Aug 2015 | $1M | Grant | – | – | |
| Mar 2015 | $2M | Grant | – | – | |
| Jul 2014 | $3.67M | Series A | – | – | – |
| Jun 2013 | $1.29M | Seed | – | – | – |
| Aug 2010 | $1.93M | Grant | – | – | |
| Aug 2010 | $298,626 | Grant | – | – | |
| Jun 2010 | $1M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Hemosonics
Hemosonics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Diagnostica Stago and U.S. Air Force.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Aerial defense and operations are conducted for national security. | af.mil | Arlington, United States | ||
Research on heart, lung, blood, and sleep disorders is conducted. | nhlbi.nih.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A portfolio of hemostasis and coagulation diagnostic products is manufactured. | 1998 | stago.com | Paris, France |
Investor details for Hemosonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hemosonics
36 people are tracked at Hemosonics (11 in leadership, 25 in team).
| Name | Role | Group |
|---|---|---|
Joe Steele | Head of Commercial, US | Leadership |
Francesco Viola | Founder & Chief Scientific Officer | Leadership |
Raymond L Szafranski Jr | Chief Financial Officer & Chief Compliance Officer | Leadership |
Deborah Winegar | VP, Clinical Affairs | Leadership |
Robert A. Roda | President & CEO | Leadership |
Deborah O. Sinclair | Head, Human Resources | Leadership |
Steve Erwine | Chief Financial Officer; Chief Compliance Officer | Leadership |
Raymond Szafranski Jr. | Chief Financial Officer & Chief Compliance Officer | Leadership |
Shaun Winnail | US Eastern Region Sales Director | Leadership |
Joseph A. Steele | Head Of Commercial - US | Leadership |
Bruce D. Spiess | Medical Director | Leadership |
Maxwell Marion-Spencer | Biostatistician | Team |
Bill Craig | Regional Sales Consultant | Team |
Robin Williamson | Clinical Research Associate | Team |
Dominick Ciccarelli | Regional Sales Consultant | Team |
David Ballering Mba | Clinical Manager – Western US | Team |
Crystal Greer | Regional Sales Consultant | Team |
Jennifer Foster | Human Resources Generalist II | Team |
Stephen Dombroski | Northeast Sales Consultant | Team |
Bryce Cook | Regional Sales Consultant | Team |
16 more people are available in the full profile.
Complete people profiles for Hemosonics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemosonics
Hemosonics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Diagnostica Stago.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A portfolio of hemostasis and coagulation diagnostic products is manufactured. | stago.com | Paris, France | 1998 | May 2017 | •••• |
Complete acquisition details for Hemosonics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Hemosonics
5 dated milestones of Hemosonics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Hemosonics is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $15.0M.
- Acquisition Acquires Diagnostica Stago.
- Exit Acquired by Diagnostica Stago.
Competitors of Hemosonics
Hemosonics has 3 listed competitors in our database, 2 of them funded. They include Perosphere Technologies, Atantares and Stasys.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| perospheretech.com | 2017 | Danbury, United States | Point-of-care coagulation diagnostics and drug delivery systems are developed. | |||
| atantares.com | 2020 | Cambridge, United States | $13.99M | Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies | ||
| stasysmedical.com | 2013 | Seattle, United States | $2.85M | Provider of POC device for analyzing blood clotting disorders and platelet dysfunction |
Detailed competitors of Hemosonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hemosonics
The website of Hemosonics (hemosonics.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▼ 30.2% vs previous month
Top companies in Hematology
3 companies that operate in the same segment as Hemosonics (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hemosonics
Complete news archive for Hemosonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemosonics
Hemosonics was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Hemosonics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Hemosonics is a funded company, having raised a total of $24.92M across 9 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 2010.
HemoSonics is a privately held medical device company founded to develop and bring to market innovative in vitro diagnostics to characterize hemostasis in a variety of clinical settings. These systems employ a patented approach named sonorheometry (SR). The products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. The company claims that this approach makes their system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. This technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors. Sonorheometry has been demonstrated in a series of peer-reviewed scientific publications and has undergone both laboratory and clinical evaluation. Standalone prototypes are undergoing further clinical and laboratory evaluation. HemoSonics LLC is developing a POC instrument, the Global Hemostasis Analyzer (GHA) that can quantify the function of the four hemostatic components, enabling correct selection of treatment. The Quantra is based on sonorheometry (SR), a novel technology able to assess not only time to clot (dependent upon the plasma coagulation factors) but also clot formation rate (dependent upon fibrinogen), clot stiffness (dependent upon fibrinogen and platelets), and time to lysis (dependent upon clot-dissolving proteins).
Hemosonics's top competitors include Perosphere Technologies, Atantares and Stasys.
Hemosonics offers Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program.
Hemosonics has made 1 acquisition, including Diagnostica Stago.
Hemosonics has 4 investors. Key investors include HHS, Diagnostica Stago, U.S. Air Force, and National Heart, Lung, and Blood Institute.
Hemosonics operates through Hemosonics, Llc.
Yes. Hemosonics was acquired by Diagnostica Stago in May 2017.